Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

PHASE2TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 28, 2023

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions
Ulcerative Colitis
Interventions
DRUG

Efavaleukin alfa

Subcutaneous (SC) injection

DRUG

Placebo

SC injection

Trial Locations (25)

1024

MIND Klinika Kft, Budapest

1033

Clinexpert Kft, Budapest

1605

Clinica Independencia, Munro

1680

Diagnostic-Consultative Center Convex EOOD, Sofia

2730

Herlev Hospital, Herlev

3012

Intesto BE, Bern

6725

Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Altalanos Orvostudomanyi Kar, Szeged

26426

Wonju Severance Christian Hospital, Wonju-si, Gangwon-do

33343

Mersin Universitesi Tip Fakultesi Hastanesi, Mersin

34741

Indian Health Service Health Research, Kissimmee

41001

Kocaeli Universitesi Tip Fakultesi Hastanesi, Kocaeli

44650

Clinica de Investigacion en Reumatologia y Obesidad SC, Guadalajra

66160

University of Kansas Medical Center, Kansas City

89081

Universitaetsklinikum Ulm, Ulm

93458

Santa Maria Gastroenterology Medical Group, Santa Maria

B7600DHK

Centro de Investigaciones Medicas Mar del Plata, Mar del Plata

B1878DVB

Cer Instituto Medico, Quilmes

277-0871

Tsujinaka Hospital Kashiwanoha, Kashiwa-shi

852-8501

Nagasaki University Hospital, Nagasaki

198-0042

Ome Medical Center, Ome-shi

82-300

NZOZ Twoje Zdrowie EL Spzoo, Elblag

50-449

Centrum Medyczne Melita Medical, Wroclaw-Krzyki

012015

Clinica Medicum, Bucharest

013812

Memorial Healthcare International SRL, Bucharest

020125

Spitalul Clinic Colentina, Bucharest

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY